Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00707057 · ClinicalTrials.gov registry record · Phase 3

Ibuprofen Extended-Release Dental Pain Study

A Phase 3 study of Pain and Post Operative Pain, sponsored by SCOLR Pharma.

Completed
Registry status
Phase 3
Development phase
256
Enrollment target
1
Study location

NCT00707057 is a Phase 3 study of Pain and Post Operative Pain that has completed, run by SCOLR Pharma. The registered enrollment target is 256 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00707057, a Phase 3 study of Pain and Post Operative Pain, has completed, sponsored by SCOLR Pharma.

COMPLETED
Registry status
Phase 3
Development phase
256 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the efficacy and safety of multiple doses of Ibuprofen 600 mg Extended-Release Tablets in a study of dental pain following extraction of third molar teeth.

Interventions

  • DRUG Placebo
  • DRUG Ibuprofen 600 mg Extended-Release Tablets

Study Locations (1)

Utah

  • Jean Brown Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2008-06
Est. Completion 2008-10
Phase Phase 3

Sponsor

SCOLR Pharma

1 total trials

What the Registry Record Tells You About NCT00707057

The ClinicalTrials.gov registry entry for NCT00707057 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (16% lower). The listed sponsor is SCOLR Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00707057 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT00707057 about?

NCT00707057 is a clinical study titled "Ibuprofen Extended-Release Dental Pain Study". The purpose of this study is to evaluate the efficacy and safety of multiple doses of Ibuprofen 600 mg Extended-Release Tablets in a study of dental pain following extraction of third molar teeth.

What is the current status of trial NCT00707057?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2008-06. Estimated completion is 2008-10.

What conditions does trial NCT00707057 study?

This clinical trial studies the following conditions: Pain, Post Operative Pain, Third Molar Extraction.

What interventions are being tested in trial NCT00707057?

The interventions under investigation include: Placebo (DRUG), Ibuprofen 600 mg Extended-Release Tablets (DRUG).

Who is sponsoring clinical trial NCT00707057?

This trial is sponsored by SCOLR Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00707057 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.